VMX-C001
CSL Commits $117M for Option to Acquire VarmX and Advance Novel Blood Clotting Therapy to Market
CSL; VarmX; VMX-C001; blood clotting drug; Factor Xa inhibitors; anticoagulants; Phase 3 clinical trial; acquisition; biotech partnership; critical bleeding; FDA fast-track